Equities researchers at Deutsche Bank assumed coverage on shares of Celgene (NASDAQ:CELG) in a research note issued to investors on Tuesday, The Fly reports. The firm set a “hold” rating on the biopharmaceutical company’s stock.
Several other analysts have also recently commented on CELG. BidaskClub upgraded Celgene from a “sell” rating to a “hold” rating in a research report on Tuesday. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Celgene in a research note on Sunday. Cantor Fitzgerald set a $112.00 price target on Celgene and gave the company a “hold” rating in a research note on Monday. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $148.32 price target for the company in a research note on Wednesday, August 16th. Finally, Atlantic Securities raised Celgene from a “neutral” rating to an “overweight” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty have assigned a buy rating and two have given a strong buy rating to the company’s stock. Celgene currently has a consensus rating of “Buy” and a consensus price target of $139.57.
Celgene (NASDAQ:CELG) traded up $1.04 on Tuesday, reaching $109.04. The company had a trading volume of 5,122,695 shares, compared to its average volume of 4,782,211. Celgene has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. The firm has a market cap of $83,526.45, a PE ratio of 16.58, a P/E/G ratio of 0.82 and a beta of 1.78.
In other news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.95% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Celgene by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after buying an additional 3,084,227 shares during the period. Vanguard Group Inc. boosted its position in shares of Celgene by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after buying an additional 1,610,056 shares during the period. State Street Corp boosted its position in shares of Celgene by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after buying an additional 723,844 shares during the period. Jennison Associates LLC boosted its position in shares of Celgene by 11.5% in the third quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock worth $2,181,818,000 after buying an additional 1,546,673 shares during the period. Finally, FMR LLC boosted its position in shares of Celgene by 5.9% in the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock worth $1,635,643,000 after buying an additional 697,250 shares during the period. 80.16% of the stock is owned by institutional investors and hedge funds.
About Celgene
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
